Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2

Prostate

Volumn 36, Issue SUPPL. 8, 1998, Pages 32-36

  Diaz, Miguel ^a   Abdul, Mansoor ^a   Hoosein, Naseema ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Interleukin 1; Interleukin 2; Interleukin 6; Neuroendocrine; Proinflammatory cytokines; Prostate cancer

Indexed keywords

CHROMOGRANIN A; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; CHROMOGRANIN; CYTOKINE; INTERLEUKIN 1;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOBLOTTING; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR DIFFERENTIATION; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; DRUG EFFECT; KINETICS; MALE; METABOLISM; NEUROSECRETION; PATHOLOGY; PROSTATE TUMOR;

CELL DIFFERENTIATION; CELL LINE; CHROMOGRANIN A; CHROMOGRANINS; CYTOKINES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKIN-6; KINETICS; MALE; NEUROSECRETORY SYSTEMS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 26844463152     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(1998)8+<32::AID-PROS6>3.0.CO;2-I     Document Type: Article

References (35)

1. Di Sant'Agnese PA, Cockett ATK: The prostatic endocrine-paracrine neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 1994;152:1927-1931.
2. Hoosein NM, Abdul M, Logothetis CJ: Significance of neuroendocrine differentiation in prostatic carcinoma. Cancer J 1996;9: 291-295.
3. Bonkhoff H, Stein U, Remberger K: Androger receptor status in endocrine-paracrine cell types of the normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat 1993; 423:291-294.
4. Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic and neoplastic human prostate: Simultaneous demonstration of cell specific epithelial markers. Hum Pathol 1994;25:42-46.
5. O'Connor DT, Frigon RP: Chromogranin A, the major catecholamine storage vesicle soluble protein. J Biol Chem 1984;259: 3237-3247.
6. O'Connor DT, Deftos LJ: Secretion of chromogranin A by peptide-producing neoplasms. N Engl J Med 1986;314:1145-1151.
7. Hoosein NM, Finn L, Hodges S, Diaz M, Abdul M: Soluble markers of prostate cancer progression. Cancer Res Ther Contr 1998;in press.
8. Abrahamsson PA, Falkmer S, Fait K, Grimelius L: The course of neuroendocrine differentiation in prostatic carcinomas. Pathol Res Pract 1989;185:373-380.
9. Cohen RJ, Glezerson G, Haffejee Z: Prostatic carcinoma: Histological and immunohistological factors affecting prognosis. Br J Urol 1990;66:405-410.
10. Kadmon D, Thompson TC, Lynch GR, Scardino FT: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;146:358-361.
11. Deftos LJ, Nakada S, Burton DW, Di Sant'Agnese PA, Cockett ATK, Abrahamsson P-A: Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996;48:58-62.
12. Cussenot O, Villette JM, Valeri A, Cariou G, Desgranchamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Duc A: Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-1343.
13. Sokoloff RL, Norton KC, Wolfert RL, Rittenhouse HG, Deftos LJ: Serum chromogranin A and PSA-forms in early-stage, untreated prostate cancers. J Urol 1996;155(suppl 696A):1539.
14. Weinstein MH, Partin AW, Veltri RW, Epstein JI: Neuroendocrine differentiation in prostate cancer: Enhanced prediction after radical prostatectomy. Hum Pathol 1996;27:683-687.
15. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY, Simons JW: Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-549.
16. Hoosein NM, Abdul M, McCabe R, Gero E, Deftos L, Banks M, Hodges S, Finn L Logothetis CJ: Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol Oncol 1995;1:246-251.
17. Patterson JC, Childs GV: Nerve growth factor in the anterior pituitary: Regulation of secretion. Endocrinology 1994;135:1697-1704.
18. McCann SM, Lyson K, Karanth M, Gimeno M, Belova N, Kamat A, Rettori V: Role of cytokines in the endocrine system. Ann NY Acad Sci 1994;739:50-63.
19. Jankovic BD: Neuroimmunomodulation, from phenomenology to molecular evidence. Ann NY Acad Sci 1994;739:1-38.
20. Blalock JE: Shared ligands and receptors as a molecular mechanism for communication between the immune and neuroendocrine systems. Ann N Y Acad Sci 1994;739:292-298.
21. Koenig JI, Snow K, Clark BD, Toni R, Cannon JG, Shaw AR, Dinerello CA, Reichlin S, Lee SL, Lechan RM: Intrinsic pituitary interleukin-1β is induced by bacterial lipopolysaccharide. Endocrinology 1990;126:3053-3058.
22. Vankelecom H, Carmeliet P, VanDamme J, Billiau A, Denef C: Production of interleukin-6 by folliculo-stellate cells of the anterior pituitary in a histiotypic cell aggregate culture system. Neuroendocrinology 1989;49:102-106.
23. Anasagasti MJ, Olaso E, Calvo F, Mendoza L, Martin JJ, Bidaurrazaga J, Vidal-Vanaclocha F: Interleukin 1-dependent and -in-dependent mouse melanoma metastases. J Natl Cancer Inst 1997;89:645-651.
24. Paciotti GF, Tamarkin L: Interleukin-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro. Mol Endocrinol 1988;2:459-464.
25. Morikawa K, Fidler IJ: Heterogeneous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines: Interferon-alpha, interferon-gamma, tumor necrosis factor, and interleukin-1. J Biol Response Modif 1989; 8:206-218.
26. Muraki J, Nakazono M: Demonstration of interleukin-1 IL-1) as an autocrine growth inhibitor in renal cancer cell line, TC-1. Jpn J Urol 1993;84:1470-1478.
27. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC Jr: Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993;53:1939-1944.
28. Li BY, Mohanraj D, Olson MC, Moradi M, Twiggs L, Carson LF, Ramakrishnan S: Human ovarian epithelial cancer cells cultures in vitro express both interleukin 1 alpha and beta genes. Cancer Res 1992;52:2248-2252.
29. Katano M, Matsuo T, Morisaki T, Naito K, Nagumo F, Kubota E, Nakamura M, Hisatsugu T, Tadano J: Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2. Cancer Immunol Immunother 1994;39:161-166.
30. Boyano DM, Garcia de Galdeano A, Smith-Zubiaga I, Canavate ML: IL-2 treatment of B16F10 melanoma cells stimulates metastatic colonization in the liver. Anticancer Res 1997;17:11135-1142.
31. Lu C, Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993;120:1281-1288.
32. Seigall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I: Expression of interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res 1990;50:7786-7788.
33. Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a risk factor for CDDP and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55:4633-4639.
34. Keller ET, Chang C, Ershler WB: Inhibition of NFkappaB activity through maintenance of IkappaB levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 1996;271:26267-26275.
35. Barnes PJ, Karin M: Nuclear factor-kappaB-A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.